Применение антидепрессантов в составе комбинированной терапии болевой формы диабетической полинейропатии

1. Wild S, Roglic G et al. Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53.
2. Дедов И.И., Ремизов О.В., Петеркова В.А. Сахарный диабет второго типа у детей и подростков. Сахарный диабет. 2001; 4: 26–31.
3. Partanen J, Niskanen L, Lehtinen J et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89–94.
4. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. 
A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150–4.
5. Veves A, Backonja M, Malik R A. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9 (6): 660–74.
6. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М.: Боргес, 2007.
7. Boulton AJM, Vinik AI, Arezzo JC et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2008; 28: 5956–62.
8. Левин О.С. Полинейропатии. М.: Медицинское Информационное Агентство, 2005.
9. Writing Team for the DCCT/EDIC Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287: 2563–9.
10. UKPDS 33. Lancet 1998; 352: 837–53.
11. Adler AI, Boyko EJ, Ahroni JH, Stensel V et al. Risk factors for diabetic peripheral sensory neuropathy: results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997; 20: 1162–7.
12. Martin CL, Albers J, Herman WH, Cleary P. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340–4.
13. Строков И.А., Баринов А.Н. Клиника, патогенез и лечение болевого синдрома при диабетической полиневропатии. Неврол. журн. 2001; 6: 47–55.
14. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250–6.
15. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008; 24 (Suppl 1): S52–7.
16. Sindrup SH, Gram LF, Brosen K et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135–44.
17. Дорожек И.Ю., Воронова Е.И. Плизил (пароксетин) при терапии непсихотических тревожных депрессий. Псих. расстройства в общей медицине. 2009; 2: 34–7.
18. Медведев В.Э., Копылов Ф.Ю., Макух Е.А. Терапия депрессий при гипертонической болезни (на модели препарата Плизил). Псих. расстройства в общей медицине 2008; 4: 51–5.
19. Данилов А.Б., Раймкулова О.К. Лечение болевых синдромов антидепрессантом венлафаксином. Журн. неврологии и психиатрии. 2009; 1: 76–9.
20. Sindrup SH, Bach FW, Madsen C et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60: 1284–9.
21. Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305.
22. Edwards KR, Glantz MJ, Button J et al. Efficacy and safety of topiramate in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Neurology 2000; 5 (Suppl 3): A81.
23. Davis JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care 1999; 22: 1909–10.
24. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110 (3): 697–706.
25. Kadiroglu AK, Sit D, Kayabasi H et al. The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008; 22 (4): 241–5.
26. Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. Diabetes Care 2000; 23: 1710–1.
27. Vinik A, Pittenger G, Anderson A et al. Topiramate improves C-fiber neuropathy and features of the dysmetabolic syndrome in type 2 diabetes. Program and abstracts of the 63rd Scientific Sessions of the American Diabetes Association; June 13–17, 
New Orleans, Louisiana 2003, Abstract A130.
28. Papp J, Simpson DM. Safety profile of treatment in diabetic peripheral neuropathic pain. Pain Med 2007; 8 (Suppl 2): S43–9.
29. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 163–8.

В.Н.Шишкова  

ФГУ Федеральный медицинский центр, Москва